Tiziana Life Sciences Ltd (NASDAQ:TLSA) Short Interest Update

Tiziana Life Sciences Ltd (NASDAQ:TLSA) was the recipient of a large growth in short interest in December. As of December 31st, there was short interest totalling 680,800 shares, a growth of 300.2% from the December 15th total of 170,100 shares. Approximately 1.0% of the company’s stock are short sold. Based on an average trading volume of 348,300 shares, the short-interest ratio is currently 2.0 days.

Tiziana Life Sciences Stock Performance

Shares of TLSA stock opened at $0.75 on Tuesday. The firm has a fifty day simple moving average of $0.88 and a 200-day simple moving average of $0.95. Tiziana Life Sciences has a twelve month low of $0.41 and a twelve month high of $1.74.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Tiziana Life Sciences stock. Zhang Financial LLC increased its stake in shares of Tiziana Life Sciences Ltd (NASDAQ:TLSA) by 24.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 69,387 shares of the company’s stock after buying an additional 13,500 shares during the quarter. Zhang Financial LLC owned about 0.07% of Tiziana Life Sciences worth $67,000 at the end of the most recent quarter.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.